Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Genes, Chromosomes & Cancer|September 25, 2018
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.
Annals of Hematology|January 17, 2009
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic SyndromesPeter Valent, Wolf-Karsten Hofmann, Guntram Büsche, et al.
The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.
European Journal of Haematology|May 17, 2021
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemiaSigrid Machherndl-Spandl, Eva Jäger, Agnes Barna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database mergeJulie Schanz, Heinz Tüchler, Francesc Solé, et al.
International Journal of Molecular Sciences|April 30, 2020
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 PatientsKlaus Geissler, Eva Jäger, Agnes Barna, et al.
The Lancet. Haematology|July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trialRichard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Haematologica|October 26, 2014
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control groupFriederike Braulke, Uwe Platzbecker, Catharina Müller-Thomas, et al.
Cancer Medicine|March 20, 2019
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trialAlexander Egle, Thomas Melchardt, Petra Obrtlíková, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Pageof 4